Profile Image

Dr Jennette Sakoff

Conjoint Lecturer

School of Environmental and Life Sciences (Chemistry)

Career Summary

Biography

Research Expertise

Dr Sakoff is an experienced cell biologist and Chief Hospital Scientist in the Department of Medical Oncology at the Calvary Mater Newcastle Hospital. Dr Sakoff is the leader of the Experimental Therapeutics Group. She has made significant contributions to cancer research particularly in the development of small molecules for the treatment of cancer. Areas of expertise includes cell culture, drug screening, cell biology, proteomics, cell cycle analysis, drug combination studies, clinical toxicity.



Teaching Expertise

Selected lectures in drug development.


Qualifications

  • PhD, University of Newcastle

Keywords

  • Breast Cancer
  • Cancer
  • Chemotherapy
  • Drug Development
  • Dynamin
  • Glioblastoma
  • PP2A

Fields of Research

CodeDescriptionPercentage
111299Oncology and Carcinogenesis not elsewhere classified100

Professional Experience

Professional appointment

DatesTitleOrganisation / Department
1/02/1996 - Chief Hospital ScientistCalvary Mater Newcastle Hospital
Medical Oncology
Australia

Awards

Research Award

YearAward
2000Young medical researcher of the year
Unknown
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Journal article (51 outputs)

YearCitationAltmetricsLink
2015Vuong QV, Hirun S, Chuen TLK, Goldsmith CD, Munro B, Bowyer MC, et al., 'Physicochemical, antioxidant and anti-cancer activity of a Eucalyptus robusta (Sm.) leaf aqueous extract', INDUSTRIAL CROPS AND PRODUCTS, 64 167-174 (2015)
DOI10.1016/j.indcrop.2014.10.061Author URL
Co-authorsVanquan Vuong, Anita Chalmers, Michael Bowyer, C Scarlett
2015Rixson JE, Abraham JR, Egoshi Y, Skelton BW, Young K, Gilbert J, et al., 'The synthesis and biological activity of novel anthracenone-pyranones and anthracenone-furans', Bioorganic and Medicinal Chemistry, (2015)

An efficient and divergent methodology for the synthesis of new anthracenone-pyranones and anthracenone-furans is described. Key reactions discussed in these syntheses include an aldehyde promoted annulation with a ß-keto-sulfoxide, a domino alkyne insertion/carbonylation/Nu-acylation and a DMEDA promoted Castro-Stephens reaction. We also report the in vitro growth inhibition of these compounds in a range of human cancer cells. The natural product BE-26554A displayed good cell growth activity on BE2-C neuroblastoma and SMA glioblastoma cell lines at 0.17 and 0.16µM (GI50), respectively. Of note, were a CF3 functionalised anthracenone 4-pyranone (chromone) derivative 22, and an anthracenone-furan derivative 54 which displayed 0.20µM and 0.38µM growth inhibition, respectively, in the BE2-C neuroblastoma cell line.

DOI10.1016/j.bmc.2015.04.032
Co-authorsAdam Mccluskey
2014Al Otaibi A, Gordon CP, Gilbert J, Sakoff JA, McCluskey A, 'The influence of ionic liquids on the Knoevenagel condensation of 1H-pyrrole-2-carbaldehyde with phenyl acetonitriles-cytotoxic 3-substituted-(1H-pyrrol-2-yl)acrylonitriles', RSC Advances, 4 19806-19813 (2014) [C1]

The Knoevenagel condensation of a series of substituted phenyl acetonitriles with 1H-pyrrole-2-carbaldehyde was examined in seven 1-butyl-3-methylimidazolium based ionic liquids and three protic ionic liquids. Of these [BMIM][Br] and [BMIM][OH], with catalytic piperidine, proved most efficient affording 3-substituted-(1H-pyrrol-2-yl)acrylonitriles 3-17 in good to excellent yields (98%) whilst utilisation of the protic ionic liquid propyl ammonium nitrate resulted in reduced yields (0-66%). Screening of the 3-substituted-(1H-pyrrol-2-yl)acrylonitriles analogues 3-17 against a panel of 11 cancer cell lines and one normal cell line allowed the identification of a series of compounds with broad spectrum cytotoxicity, but more interestingly a significant degree of MCF-7 breast cancer cell line specificity was evident with 6 (7 to >25 fold) and 13 (5.7 to >80 fold). Other analogues show high level of efficacy against specific cell lines with 10 showing excellent activity against MCF-7 (GI50 = 1.7 µM) and A431 (GI50 = 2.8 µM) cell lines. The most promising of the compounds identified herein were the 4-CF3 substituted 10 and the 3,4-dichloro substituted 13 with excellent activities against MCF-7 and A431 cell lines. The 3,4-dichloro-13 was a 0.56 µM potent inhibitor of MCF-7 cell growth. © 2014 the Partner Organisations.

DOI10.1039/c3ra47418f
Co-authorsAdam Mccluskey
2014Dyson L, Young KA, McCluskey A, Wright AD, Sakoff JA, 'Synthesis and anticancer activity of focused compound libraries from the natural product lead, oroidin', Bioorganic and Medicinal Chemistry, 22 1690-1699 (2014) [C1]

Oroidin (1), (E)-N-(3-(2-amino-1H-imidazol-4-yl)allyl)-4,5-dibromo-1H- pyrrole-2-carboxamide, is a pyrrole alkaloid isolated from the marine sponge Agelas oroides. Routine screening in a panel of twelve cancer cell lines revealed 1 to be poorly cytotoxic with the 50% growth inhibition concentration (GI) of 42 µM in MCF-7 (breast) cells and 24 µM in A2780 (ovarian) cells and >50 µM in all other cell lines tested. The development of eight focused libraries comprising thirty compounds total identified N-(biphenyl-4-ylmethyl)-1H-pyrrole-2-carboxamide (4l), N-benzyl-4,5-dibromo-1H- pyrrole-2-carboxamide (5a) and N-(biphenyl-4-ylmethyl)-4,5-dibromo-1H-pyrrole-2- carboxamide (5l) as potent inhibitors of cell growth in our panel of cell lines. Of these compounds GI values of <5 µM were observed with 4l against HT29 (colon) and SW480 (colon); 5a against HT29; and 5l against HT29, SW480, MCF-7, A431 (skin), Du145 (prostate), BE2-C (neuroblastoma) and MIA (pancreas) cell lines. As a cancer class, colon cancer appears to be more sensitive to the oroidin series of compounds, with analogue 5l being the most active. © 2014 Elsevier Ltd. All rights reserved.

DOI10.1016/j.bmc.2014.01.021
CitationsScopus - 2Web of Science - 3
Co-authorsAdam Mccluskey
2014Vuong QV, Sadeqzadeh E, Hirun S, Goldsmith CD, Zammitt N, Bowyer MB, et al., 'Phenolic Compounds, Antioxidant and Anti-Cancer Properties of the Australian Maroon Bush Scaevola spinescens (Goodeniaceae)', Journal of Bioanalysis & Biomedicine, S12 (2014) [C1]
DOI10.4172/1948-593X.S12-002
Co-authorsMichael Bowyer, Rick Thorne, Vanquan Vuong, Judith Weidenhofer, C Scarlett
2014Gordon CP, Hizartzidis L, Tarleton M, Sakoff JA, Gilbert J, Campbell BE, et al., 'Discovery of acrylonitrile-based small molecules active against Haemonchus contortus', MEDCHEMCOMM, 5 159-164 (2014) [C1]
DOI10.1039/c3md00255aAuthor URL
CitationsScopus - 2Web of Science - 3
Co-authorsAdam Mccluskey
2013Tarleton M, Dyson L, Gilbert J, Sakoff JA, McCluskey A, 'Focused library development of 2-phenylacrylamides as broad spectrum cytotoxic agents', BIOORGANIC & MEDICINAL CHEMISTRY, 21 333-347 (2013) [C1]
DOI10.1016/j.bmc.2012.10.003Author URL
CitationsScopus - 5Web of Science - 4
Co-authorsAdam Mccluskey
2013McCluskey A, Daniel JA, Hadzic G, Ngoc C, Clayton EL, Mariana A, et al., 'Building a Better Dynasore: The Dyngo Compounds Potently Inhibit Dynamin and Endocytosis', TRAFFIC, 14 1272-1289 (2013)
DOI10.1111/tra.12119Author URL
CitationsWeb of Science - 18
Co-authorsAdam Mccluskey
2013McCluskey A, Daniel JA, Hadzic G, Chau N, Clayton EL, Mariana A, et al., 'Building a Better Dynasore: The Dyngo Compounds Potently Inhibit Dynamin and Endocytosis', Traffic, 14 1272-1289 (2013) [C1]
DOI10.1111/tra.12119
CitationsScopus - 20
Co-authorsAdam Mccluskey
2013Deane FM, O'Sullivan EC, Maguire AR, Gilbert J, Sakoff JA, McCluskey A, McCarthy FO, 'Synthesis and evaluation of novel ellipticines as potential anti-cancer agents', Organic & Biomolecular Chemistry, 11 1334-1344 (2013) [C1]
DOI10.1039/c2ob27186aAuthor URL
CitationsScopus - 7Web of Science - 9
Co-authorsAdam Mccluskey
2013McGeachie AB, Odell LR, Quan A, Daniel JA, Chau N, Hill TA, et al., 'Pyrimidyn compounds: Dual-action small molecule pyrimidine-based dynamin inhibitors', ACS Chemical Biology, 8 1507-1518 (2013) [C1]
DOI10.1021/cb400137p
CitationsScopus - 6Web of Science - 6
Co-authorsAdam Mccluskey
2012Tarleton MJ, Gilbert J, Sakoff JA, McCluskey A, 'Synthesis and anticancer activity of a series of norcantharidin analogues', European Journal of Medicinal Chemistry, 54 573-581 (2012) [C1]
CitationsScopus - 7Web of Science - 7
Co-authorsAdam Mccluskey
2012Tarleton MJ, Gilbert J, Sakoff JA, McCluskey A, 'Cytotoxic 2-phenyacrylnitriles, the importance of the cyanide moiety and discovery of potent broad spectrum cytotoxic agents', European Journal of Medicinal Chemistry, 57 65-73 (2012) [C1]
DOI10.1016/j.ejmech.2012.09.019
CitationsScopus - 8Web of Science - 8
Co-authorsAdam Mccluskey
2012Garg MB, Lincz L, Adler K, Scorgie FE, Ackland S, Sakoff JA, 'Predicting 5-Fluorouracil toxicity in colorectal cancer patients from peripheral blood cell telomere length - A multivariate analysis', British Journal of Cancer, 107 1525-1533 (2012) [C1]
CitationsScopus - 4Web of Science - 5
Co-authorsStephen Ackland, Lisa Lincz
2011Garg MB, Sakoff JA, Ackland S, 'A simple HPLC method for plasma level monitoring of mitotane and its two main metabolites in adrenocortical cancer patients', Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 879 2201-2205 (2011) [C1]
CitationsScopus - 5Web of Science - 5
Co-authorsStephen Ackland
2011Tarleton MJ, Gilbert J, Robertson MJ, McCluskey A, Sakoff JA, 'Library synthesis and cytotoxicity of a family of 2-phenylacrylonitriles and discovery of an estrogen dependent breast cancer lead compound', MedChemComm, 2 31-37 (2011) [C1]
DOI10.1039/c0md00147c
CitationsScopus - 11Web of Science - 11
Co-authorsAdam Mccluskey
2011Campbell BE, Tarleton MJ, Gordon CP, Sakoff JA, Gilbert J, McCluskey A, Gasser RB, 'Norcantharidin analogues with nematocidal activity in Haemonchus contortus', Bioorganic and Medicinal Chemistry Letters, 21 3277-3281 (2011) [C1]
DOI10.1016/j.bmcl.2011.04.031
CitationsScopus - 17Web of Science - 19
Co-authorsAdam Mccluskey
2011Robertson MJ, Gordon CP, Gilbert J, McCluskey A, Sakoff JA, 'Norcantharimide analogues possessing terminal phosphate esters and their anti-cancer activity', Bioorganic & Medicinal Chemistry, 19 5734-5741 (2011) [C1]
DOI10.1016/j.bmc.2011.01.031
CitationsScopus - 9Web of Science - 10
Co-authorsAdam Mccluskey
2010Joshi S, Perera S, Gilbert J, Smith CM, Mariana A, Gordon CP, et al., 'The Dynamin inhibitors MiTMAB and OcTMAB induce Cytokinesis failure and inhibit cell proliferation in human cancer cells', Molecular Cancer Therapeutics, 9 1995-2006 (2010) [C1]
DOI10.1158/1535-7163.mct-10-0161
CitationsScopus - 25Web of Science - 27
Co-authorsAdam Mccluskey
2010Thaqi A, Scott JL, Gilbert J, Sakoff JA, McCluskey A, 'Synthesis and biological activity of Delta-5,6-norcantharimides: Importance of the 5,6-bridge', European Journal of Medicinal Chemistry, 45 1717-1723 (2010) [C1]
DOI10.1016/j.ejmech.2010.01.004
CitationsScopus - 20Web of Science - 18
Co-authorsAdam Mccluskey
2010De Bock CE, Garg ML, Scott NM, Sakoff JA, Scorgie FE, Ackland S, Lincz L, 'Association of thymidylate synthase enhancer region polymorphisms with thymidylate synthase activity in vivo', Pharmacogenomics Journal, 1-8 (2010) [C1]
DOI10.1038/tpj.2010.43
CitationsScopus - 7Web of Science - 7
Co-authorsLisa Lincz, Manohar Garg, Stephen Ackland
2009Sauer B, Gilbert J, Sakoff JA, McCluskey A, 'Synthesis of 4-substituted-3-hydroxy-5-oxo-10-oxa-4-azatricyclo[5.2.1]dec-3-yl Acetic Acid Ethyl Esters as Norcantharidin Analogues', Letters in Drug Design & Discovery, 6 1-7 (2009) [C1]
DOI10.2174/157018009787158535
CitationsScopus - 7Web of Science - 7
Co-authorsAdam Mccluskey
2009Hill TA, Gordon CP, McGeachie AB, Venn-Brown B, Odell L, Chau N, et al., 'Inhibition of dynamin mediated endocytosis by the dynoles-synthesis and functional activity of a family of indoles', Journal of Medicinal Chemistry, 52 3762-3773 (2009) [C1]
DOI10.1021/jm900036m
CitationsScopus - 62Web of Science - 61
Co-authorsAdam Mccluskey
2009Holland IP, McCluskey A, Sakoff JA, Gilbert J, Chau N, Robinson PJ, et al., 'Steroids from an Australian Sponge Psammoclema sp', Journal of Natural Products, 72 102-106 (2009) [C1]
DOI10.1021/np800688f
CitationsScopus - 4Web of Science - 3
Co-authorsAdam Mccluskey
2008Lincz L, Mudge L-M, Scorgie FE, Sakoff JA, Hamilton C, Seldon MR, 'Quantification of hTERT splice variants in melanoma by SYBR green real-time polymerase chain reaction indicates a negative regulatory role for the [beta symbol] deletion variant', Neoplasia, 10 1131-1137 (2008) [C1]
DOI10.1593/neo.08644
CitationsScopus - 21Web of Science - 20
Co-authorsLisa Lincz
2008Hill TA, Stewart SG, Gordon CP, Ackland SR, Gilbert J, Sauer B, et al., 'Norcantharidin analogues: Synthesis, anticancer activity and protein phosphatase 1 and 2A inhibition', ChemMedChem, 3 1878-1892 (2008) [C1]
DOI10.1002/cmdc.200800192
CitationsScopus - 32Web of Science - 32
Co-authorsStephen Ackland, Adam Mccluskey
2007Hill TA, Stewart SG, Sauer B, Gilbert J, Ackland S, Sakoff JA, McCluskey A, 'Heterocyclic substituted cantharidin and norcantharidin analogues-synthesis, protein phosphatase (1 and 2A) inhibition, and anti-cancer activity', Bioorganic and Medicinal Chemistry Letters, 17 3392-3397 (2007) [C1]
DOI10.1016/j.bmcl.2007.03.093
CitationsScopus - 49Web of Science - 45
Co-authorsAdam Mccluskey, Stephen Ackland
2007Hill TA, Stewart SG, Ackland S, Gilbert J, Sauer B, Sakoff JA, McCluskey A, 'Norcantharimides, synthesis and anticancer activity: Synthesis of new norcantharidin analogues and their anticancer evaluation', Bioorganic and Medicinal Chemistry, 15 6126-6134 (2007) [C1]
DOI10.1016/j.bmc.2007.06.034
CitationsScopus - 51Web of Science - 49
Co-authorsAdam Mccluskey, Stephen Ackland
2007Stewart SG, Hill TA, Gilbert J, Ackland S, Sakoff JA, McCluskey A, 'Synthesis and biological evaluation of norcantharidin analogues: Towards PP1 selectivity', Bioorganic and Medicinal Chemistry, 15 7301-7310 (2007) [C1]
DOI10.1016/j.bmc.2007.08.028
CitationsScopus - 33Web of Science - 27
Co-authorsAdam Mccluskey, Stephen Ackland
2004Lincz L, Scorgie F, Sakoff J, Fagan K, Ackland S, Enno A, 'Telomere length predicts neutrophil recovery in absence of G-CSF after autologous peripheral blood stem cell transplantation', Bone Marrow Transplant, 34 439-445 (2004) [C1]
DOI10.1038/sj.bmt.1704607
CitationsScopus - 3Web of Science - 3
Co-authorsStephen Ackland, Lisa Lincz
2004Sakoff JA, Howitt IJ, Ackland S, McCluskey A, 'Serine/threonine protein phosphatase inhibition enhances the effect of thymidylate synthase inhibition', Cancer Chemotherapy and Pharmacology, 53 225-232 (2004) [C1]
DOI10.1007/s00280-003-0730-9
CitationsScopus - 8Web of Science - 7
Co-authorsAdam Mccluskey, Stephen Ackland
2004Hart ME, Chamberlin AR, Walkom CC, Sakoff JA, McCluskey A, 'Modified norcantharidins: synthesis, protein phosphatases 1 and 2A inhibition, and anticancer activity', Bioorganic & Medicinal Chemistry Letters, 14 1969-1973 (2004) [C1]
DOI10.1016/j.bmcl.2004.01.093
CitationsScopus - 66Web of Science - 64
Co-authorsAdam Mccluskey
2004Sakoff JA, McCluskey A, 'Protein Phosphatase Inhibition: Structure Based Design. Towards New Therapeutic Agents', Current Pharmaceutical Design, 10 1139-1159 (2004) [C1]
DOI10.2174/1381612043452686
CitationsScopus - 46Web of Science - 44
Co-authorsAdam Mccluskey
2003Ackland S, Bowyer MC, Baldwin ML, Garner JA, Walkom CC, Sakoff JA, McCluskey A, 'Cantharidin analogues: synthesis and evaluation of growth inhibition in a panel of selected tumour cell lines', Bioorganic Chemistry, 31 68-79 (2003) [C1]
DOI10.1016/S0045-2068(02)00524-2
CitationsScopus - 72Web of Science - 61
Co-authorsMichael Bowyer, Adam Mccluskey, Stephen Ackland
2002McCluskey A, Sim A, Sakoff J, 'Serine-threonine protein phosphatase inhibitors: Development of potential therapeutic strategies', Journal of Medicinal Chemistry, 45 1151-1175 (2002) [C1]
CitationsScopus - 178Web of Science - 176
Co-authorsAdam Mccluskey, Alistair Sim
2002Sakoff J, Ackland S, Baldwin ML, Atherton MA, McCluskey A, 'Anticancer activity and protein phosphatase 1 and 2A inhibition of a new generation of cantharidin analogues', Investigational New Drugs, 20 1-11 (2002) [C1]
CitationsScopus - 61Web of Science - 53
Co-authorsMirella Atherton, Stephen Ackland, Adam Mccluskey
2002McCluskey A, Ackland S, Gardiner E, Walkom CC, Sakoff J, 'The inhibition of protein phosphatases 1 and 2A: a new target for rational anti-cancer drug design?', Anti-Cancer Drug Design, 16 291-303 (2002) [C1]
CitationsScopus - 27Web of Science - 22
Co-authorsStephen Ackland, Adam Mccluskey
2002McCluskey A, Atherton MA, Walkom CC, Bowyer M, Sim A, Young D, Sakoff J, 'The first two cantharidin analogues displaying PP1 selectivity', Bioorganic & Medicinal Chemistry Letters, 12 391-393 (2002) [C1]
CitationsScopus - 39Web of Science - 38
Co-authorsAdam Mccluskey, Mirella Atherton, Alistair Sim, Michael Bowyer
2002Garg MB, Sevester JC, Sakoff JA, Ackland SP, 'Simple liquid chromatographic method for the determination of uracil and dihydrouracil plasma levels: a potential pretreatment predictor of 5-fluorouracil toxicity', JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 774 223-230 (2002)
DOI10.1016/S1570-0232(02)00239-8Author URL
CitationsScopus - 35Web of Science - 30
Co-authorsStephen Ackland
2002Sakoff J, De Waal E, Garg M, Denham J, Scorgie F, Enno A, et al., 'Telomere Length in Haemopoietic Stem Cells can be Determined from that of Mononuclear Blood Cells or Whole Blood', Leukemia and Lymphoma, 43(10) 2017-2020 (2002) [C1]
CitationsScopus - 21Web of Science - 22
Co-authorsLisa Lincz, Stephen Ackland
2001McCluskey A, Walkom CC, Bowyer MC, Ackland SP, Gardiner E, Sakoff JA, 'Cantharimides: A new class of modified cantharidin analogues inhibiting protein phosphatases 1 and 2A', Bioorganic & Medicinal Chemistry Letters, 11 2941-2946 (2001) [C1]
CitationsScopus - 55Web of Science - 55
Co-authorsAdam Mccluskey, Michael Bowyer, Stephen Ackland
2001McCluskey A, Sakoff JA, 'Small molecule inhibitors of serine/threonine protein phosphatases.', Mini reviews in medicinal chemistry, 1 43-55 (2001)

Serine/threonine protein phosphatases have long been ignored as potential therapeutic targets for two reasons, one the biochemical significance of these proteins has not been appreciated and two, many natural protein phosphatase inhibitors are potent toxins and are considered unsuitable for clinical use. This review outlines the biochemical role of this protein family in cancer, cystic fibrosis, immunosuppression and, cardiac and neurological disorders. Particular emphasis is also given to the synthesis of selective small molecule inhibitors and their clinical exploitation.

CitationsScopus - 56
Co-authorsAdam Mccluskey
2000McCluskey A, Atherton MA, Mudgee L, Sim A, Sakoff JA, Quinn R, 'Anhydride modified cantharidin analogues. Is ring opening important in the inhibition of protein phosphatase 2A?', European Journal of Medicinal Chemistry, 35 957-964 (2000) [C1]
CitationsScopus - 41Web of Science - 38
Co-authorsAlistair Sim, Mirella Atherton, Adam Mccluskey
2000Sakoff J, Ackland S, 'Thymidylate synthase inhibition induces S-phase arrest, biphasic mitochondrial alterations and caspase-dependent apoptosis in leukaemia cells', Cancer Chemotherapy and Pharmacology, 46 477-487 (2000) [C1]
CitationsScopus - 29Web of Science - 26
Co-authorsStephen Ackland
2000Bowyer MC, 'Anhydride Modified Cantharidin Analogues: Synthesis, Inhibition of Protein Phosphatases 1 and 2A and Anticancer Activity', Bioorganic & Medicinal Chemistry Letters, 10 1687-1690 (2000) [C1]
CitationsScopus - 69Web of Science - 69
Co-authorsMichael Bowyer, Alistair Sim, Adam Mccluskey
2000Sakoff JA, McCluskey A, Sims ATR, Stewart JF, Ackland SP, 'A counter intuitive therapy for the treatment of cancer: Inhibition of protein phosphatases 1 and 2A by cantharidin (Spanish Fly) analogues.', CLINICAL CANCER RESEARCH, 6 4495S-4495S (2000)
Author URL
Co-authorsStephen Ackland, Adam Mccluskey
1996Sakoff J, Dunstan RH, Murdoch RN, 'Uterine lipid alterations during early pseudopregnancy and following the artificial induction of decidualization by Concanavalin A in QS mice', Molecular reproductive Development, 44 93-102 (1996) [C1]
CitationsScopus - 1
Co-authorsHugh Dunstan
1996Sakoff JA, Murdoch RN, 'The role of calcium in the artificially induced decidual cell reaction in pseudopregnant mice', BIOCHEMICAL AND MOLECULAR MEDICINE, 57 81-90 (1996)
DOI10.1006/bmme.1996.0013Author URL
CitationsScopus - 7Web of Science - 8
1996Sakoff J, Murdoch RN, 'The role of calcium ions in the Concanavalin A induced decidual cell reaction in pseudopregnant mice', Biochemical and Molecular Medicine, 57 81-90 (1996) [C1]
1995Sakoff J, Murdoch RN, 'Uterine receptivity to the artificial deciduogenic agent, Concanavalin A in pseudopregnant', Reproduction, Fertility and Development, 7 1095-1100 (1995) [C1]
CitationsScopus - 2Web of Science - 2
1994Sakoff J, Murdoch RN, 'Alterations in uterine calcium ions during the induction of the decidual cell reaction in pseudopregnant mice', journal of reproduction and fertility, 101 97-102 (1994) [C1]
CitationsScopus - 13Web of Science - 14
Show 48 more journal articles

Conference (19 outputs)

YearCitationAltmetricsLink
2014Sakoff J, Gilbert J, McCluskey A, 'Small molecules selectively targeting breast cancer cells', EUROPEAN JOURNAL OF CANCER, European Org Res & Treatment Canc, Barcelona, SPAIN (2014) [E3]
Author URL
Co-authorsAdam Mccluskey
2014Garg MB, Sakoff JA, Johnson C, Bonaventura A, Ackland SP, 'CLINICAL STUDY OF MITOTANE PHARMACODYNAMICS IN ADRENOCORTICAL CANCER IN CHILDREN AND ADULTS', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Author URL
Co-authorsStephen Ackland
2014Gilbert J, Dun MD, De Iuliis GN, McCluskey A, Sakoff JA, 'SELECTIVELY TARGETING BREAST CANCER CELLS VIA CHECKPOINT ACTIVATION', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Author URL
Co-authorsGeoffry DeiuliIs, Adam Mccluskey, Matt Dun
2014Gilbert J, McCluskey A, Sakoff JA, 'ENHANCING RADIATION EFFECTS FOR THE TREATMENT OF BRAIN CANCER', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Author URL
Co-authorsAdam Mccluskey
2014Prawira A, Garg MB, Sakoff JA, Lincz LF, Adler K, Scorgie FE, Ackland SP, 'FACTORS PREDICTING RESPONSE AND SURVIVAL IN COLORECTAL CANCER PATIENTS RECEIVING ADJUVANT 5-FLUOROURACIL CHEMOTHERAPY: 10-YEAR FOLLOW-UP OF A PROSPECTIVE PATIENT COHORT', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Author URL
Co-authorsLisa Lincz, Stephen Ackland
2013Sakoff JA, Gilbert J, Tarleton M, Robertson M, McCluskey A, 'New small molecules targeting breast cancer', INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2013) [E3]
Author URL
Co-authorsAdam Mccluskey
2012Sakoff JA, Garg MB, Lincz L, Adler K, Scorgie FE, Ackland S, 'Predicting chemotherapy-induced toxicity in cancer patients from peripheral blood telomere length', European Journal of Cancer, Barcelona, Spain (2012) [E3]
Co-authorsLisa Lincz, Stephen Ackland
2010Garg M, Sakoff JA, Ackland S, 'A simple HPLC method to measure plasma mitotane and its two main metabolites in adrenocortical cancer patients', AACR 101st Annual Meeting 2010. Abstracts, Washington, DC (2010) [E3]
Co-authorsStephen Ackland
2010Joshi S, Gaddipatti S, Gilbert J, Smith CM, Gordon CP, Sakoff JA, et al., 'Dynamin inhibition: A new therapeutic approach for the treatment of cancer', AACR 101st Annual Meeting 2010. Abstracts, Washington, DC (2010) [E3]
Co-authorsAdam Mccluskey
2010Sakoff JA, Garg M, Adler K, Scorgie FE, Lincz L, Ackland S, 'Telomere length in peripheral blood mononuclear cells (PBMNC) predicts for leukopenia, neutropenia and mucositis in colorectal cancer patients treated with 5FU', AACR 101st Annual Meeting 2010. Abstracts, Washington, DC (2010) [E3]
Co-authorsLisa Lincz, Stephen Ackland
2010Sakoff JA, Garg M, Adler K, Scorgie FE, Lincz L, Ackland S, 'Short telomeres in PBMNC predicts for haematological toxicity in colorectal cancer patients treated with 5FU', Sydney Cancer Conference 2010. Profiling Risk, Personalising Treatment and Predicting Outcomes. Conference Program and Abstract Book, Sydney, NSW (2010) [E3]
Co-authorsLisa Lincz, Stephen Ackland
2010Chircop M, Perera S, Ma MPC, Lau H, Gilbert J, Jones NC, et al., 'Dynole 34-2 is a potent inhibitor of dynamin that induces cell death following cytokinesis failure and suppresses glioblastoma tumour growth in vivo', OzBio 2010: The Molecules of Life - from Discovery to Biotechnology. Poster Abstracts, Melbourne, Australia (2010) [E3]
Co-authorsAdam Mccluskey
2002Sakoff JA, Ackland SP, Garg MB, Walkom CC, McCluskey A, 'Protein phosphatase 2A, a novel and unexplored anticancer target', EUROPEAN JOURNAL OF CANCER, FRANKFURT, GERMANY (2002)
Author URL
Co-authorsStephen Ackland, Adam Mccluskey
1996Sakoff JA, Murdoch RN, 'Uterine decidualization and calcium ion alterations in pseudopregnant mice' (1996) [E1]
1995Sakoff JA, Dunstan RH, Murdoch RN, 'The n-3 and n-6 fatty acid profile of uterine tissue following the Concanavalin A induced decidual cell reaction in mice', Unknown, Unknown (1995) [E1]
1995Sakoff JA, Dunstan RH, Murdoch RN, 'Alterations in uterine saturated fatty acids and cholesterol accompany induction of decidualization in pseudopregnant mice' (1995) [E1]
1994Sakoff JA, Murdoch RN, 'The period of uterine receptivity in the pseudopregnant Quackenbush Special mouse as defined by the deciduogenic lectin, Concanavalin A' (1994) [E1]
1993Sakoff JA, Murdoch RN, Dunstan RH, 'Changes in the poly-unsaturated fatty acid composition of the uterus during induction of the decidual cell reaction in pseudopregnant mice', Changes in the poly-unsaturated fatty acid composition of the uterus during induction of the decidual cell reaction in pseudopregnant mice, Unknown (1993) [E1]
1991Sakoff J, Murdoch RN, 'Uterine decidualization and calcium ion alterations in pseudopregnant mice' (1991) [E1]
Show 16 more conferences
Edit

Grants and Funding

Summary

Number of grants27
Total funding$2,607,036

Click on a grant title below to expand the full details for that specific grant.


20142 grants / $35,000

Enhancing radiation effects for the treatment of brain cancer $25,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Jennette Sakoff, Dr JAYNE Gilbert, Professor Adam McCluskey
SchemeProject Grant
RoleLead
Funding Start2014
Funding Finish2014
GNoG1301412
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

An Investigation on the Consensus Between Different Genomic and Transcriptomic Results in Breast Cancer$10,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamMs Heloisa Milioli, Professor Pablo Moscato, Doctor Jennette Sakoff, Associate Professor Regina Berretta
SchemeJennie Thomas Medical Research Travel Grant
RoleInvestigator
Funding Start2014
Funding Finish2014
GNoG1401334
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

20131 grants / $210,000

The integration of bioinformatics, chemoinformatics, and toxicogenomics methods: a new approach for the identification of combination tailored therapies and novel drug targets in breast cancer$210,000

Funding body: Cancer Institute NSW

Funding bodyCancer Institute NSW
Project TeamProfessor Pablo Moscato, Doctor Jennette Sakoff, Associate Professor Regina Berretta
SchemeNSW Premier's Awards for Outstanding Cancer Research: "Big Data, Big Impact" Grant
RoleInvestigator
Funding Start2013
Funding Finish2014
GNoG1300826
Type Of FundingOther Public Sector - State
Category2OPS
UONY

20127 grants / $755,794

The role of clathrin in the spindle assembly checkpoint and as an anticancer target$245,100

Funding body: NHMRC (National Health & Medical Research Council)

Funding bodyNHMRC (National Health & Medical Research Council)
Project TeamMs Megan Chircop, Professor Adam McCluskey, Professor Phillip Robinson, Doctor Jennette Sakoff
SchemeProject Grant
RoleInvestigator
Funding Start2012
Funding Finish2012
GNoG1101106
Type Of FundingAust Competitive - Commonwealth
Category1CS
UONY

High-Resolution Isoelectric Phosphoprotein Signalling System for Signalling Research, Biomarker Validation and Drug Development – Equipment Grant$143,394

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Rick Thorne, Professor Xu Dong Zhang, Professor Hubert Hondermarck, Conjoint Professor Stephen Ackland, Doctor Lisa Lincz, Doctor Jennette Sakoff, Emeritus Professor Leonie Ashman
SchemeProject Grant
RoleInvestigator
Funding Start2012
Funding Finish2012
GNoG1200555
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

Identification of a novel target for the treatment of hormone positive breast cancer$30,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Jennette Sakoff, Dr JAYNE Gilbert, Professor Adam McCluskey
SchemeBreast Cancer Project Grant
RoleLead
Funding Start2012
Funding Finish2012
GNoG1200716
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

Mitotane pharmacodynamics in Adrenocortical Cancer in children and adults $20,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamConjoint Professor Stephen Ackland, Doctor Jennette Sakoff, Ms MADHU Garg
SchemeProject Grant
RoleInvestigator
Funding Start2012
Funding Finish2012
GNoG1200319
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

The role of clathrin in the spindle assembly checkpoint and as an anticancer target$15,000

Funding body: NSW Trade & Investment

Funding bodyNSW Trade & Investment
Project TeamProfessor Adam McCluskey, Doctor Jennette Sakoff
SchemeTechVouchers Program
RoleInvestigator
Funding Start2012
Funding Finish2012
GNoG1200796
Type Of FundingOther Public Sector - State
Category2OPS
UONY

Ultrasonic Homogenizer System and -80 ºC Freezers for chemical and biological sample storage$10,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding bodyNHMRC (National Health & Medical Research Council)
Project TeamProfessor Adam McCluskey, Professor Eileen McLaughlin, Professor Peter Lewis, Ms Belinda Nixon, Doctor Shaun Roman, Doctor Jennette Sakoff, Doctor Ian Grainge
SchemeEquipment Grant
RoleInvestigator
Funding Start2012
Funding Finish2012
GNoG1100986
Type Of FundingOther Public Sector - Commonwealth
Category2OPC
UONY

20114 grants / $1,054,792

Development of pthaladyn-based dynamin I-selective inhibitors for treatment of epilepsy$544,831

Funding body: NHMRC (National Health & Medical Research Council)

Funding bodyNHMRC (National Health & Medical Research Council)
Project TeamProfessor Adam McCluskey, Professor Phillip Robinson, Professor Terence O'Brien, Ms Megan Chircop, Doctor Jennette Sakoff
SchemeDevelopment Grants
RoleInvestigator
Funding Start2011
Funding Finish2011
GNoG1000740
Type Of FundingAust Competitive - Commonwealth
Category1CS
UONY

Chemical Biology$444,961

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamProfessor Adam McCluskey, Doctor Warwick Belcher, Doctor Ian Grainge, Professor Christopher Grof, Professor Peter Lewis, Professor Eileen McLaughlin, Doctor Shaun Roman, Conjoint Professor Ray Rose, Doctor Jennette Sakoff, Doctor Nikki Verrills
SchemePriority Research Centre
RoleInvestigator
Funding Start2011
Funding Finish2011
GNoG1100052
Type Of FundingInternal
CategoryINTE
UONY

Computational prediction and functional clarification of novel drug combination strategies for the treatment of brain tumours$50,000

Funding body: Maitland Cancer Appeal Committee

Funding bodyMaitland Cancer Appeal Committee
Project TeamProfessor Pablo Moscato, Mr Dan Johnstone, Associate Professor Regina Berretta, Doctor Luke Mathieson, Professor Manuel Graeber, Doctor Jennette Sakoff
SchemeResearch Project
RoleInvestigator
Funding Start2011
Funding Finish2011
GNoG1100275
Type Of FundingDonation - Aust Non Government
Category3AFD
UONY

Eppendorf mastercycler pro with thermomixer comfort and 5430R centrifuge$15,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding bodyNHMRC (National Health & Medical Research Council)
Project TeamProfessor Eileen McLaughlin, Professor Peter Lewis, Professor Adam McCluskey, Conjoint Professor Keith Jones, Associate Professor Brett Nixon, Doctor Shaun Roman, Doctor Jennette Sakoff, Doctor Ian Grainge, Doctor Janet Holt, Doctor Xiao Yang
SchemeEquipment Grant
RoleInvestigator
Funding Start2011
Funding Finish2011
GNoG1100028
Type Of FundingOther Public Sector - Commonwealth
Category2OPC
UONY

20101 grants / $35,000

New small molecules for the treatment of neuroblastoma$35,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDr JAYNE Gilbert, Doctor Jennette Sakoff, Ms Megan Chircop
SchemePaediatric Oncology Project Grant
RoleInvestigator
Funding Start2010
Funding Finish2010
GNoG0900192
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

20072 grants / $352,000

FACSAria - Fluorescence activated cell sorter$300,000

Funding body: Cancer Institute NSW

Funding bodyCancer Institute NSW
Project TeamDoctor Nikki Verrills, Emeritus Professor Leonie Ashman, Laureate Professor John Aitken, Professor Eileen McLaughlin, Professor Alistair Sim, Doctor Rick Thorne, Doctor Jennette Sakoff
SchemeResearch Infrastructure Grants
RoleInvestigator
Funding Start2007
Funding Finish2007
GNoG0187666
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

HMRI Contribution toward FACSAria - Fluorescence activated cell sorter$52,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Nikki Verrills, Emeritus Professor Leonie Ashman, Laureate Professor John Aitken, Professor Eileen McLaughlin, Professor Alistair Sim, Doctor Rick Thorne, Doctor Jennette Sakoff
SchemeEquipment Grant
RoleInvestigator
Funding Start2007
Funding Finish2007
GNoG0188207
Type Of FundingOther Public Sector - State
Category2OPS
UONY

20061 grants / $11,000

Overcoming radiation resistance in malignant melanoma$11,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Lisa Lincz, Doctor Jennette Sakoff
SchemeProject Grant
RoleInvestigator
Funding Start2006
Funding Finish2006
GNoG0186528
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

20031 grants / $50,000

High Pressure and Fluorous Approaches to fostriecin libraries: New Therapeutic Opportunities.$50,000

Funding body: ARC (Australian Research Council)

Funding bodyARC (Australian Research Council)
Project TeamProfessor Adam McCluskey, Assoc. Prof David Young, Doctor Jennette Sakoff
SchemeDiscovery Projects
RoleInvestigator
Funding Start2003
Funding Finish2003
GNoG0182117
Type Of FundingAust Competitive - Commonwealth
Category1CS
UONY

20021 grants / $10,000

New targets for chemotherapy: anti-cancer drugs that target protein phosphatases$10,000

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamProfessor Adam McCluskey, Conjoint Professor Stephen Ackland, Doctor Jennette Sakoff
SchemeProject Grant
RoleInvestigator
Funding Start2002
Funding Finish2002
GNoG0181459
Type Of FundingInternal
CategoryINTE
UONY

20013 grants / $23,450

Synergistic interaction between thymidylate synthase and protein phosphatase inhibition in colon cancer cells$10,450

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamDoctor Jennette Sakoff
SchemeEarly Career Researcher Grant
RoleLead
Funding Start2001
Funding Finish2001
GNoG0181233
Type Of FundingInternal
CategoryINTE
UONY

Predicting bone marrow regeneration in cancer patients through the use of telomere quantitative (Q)-FISH$10,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Lisa Lincz, Doctor Jennette Sakoff
SchemeLions Club of Stroud
RoleInvestigator
Funding Start2001
Funding Finish2001
GNoG0181502
Type Of FundingDonation - Aust Non Government
Category3AFD
UONY

Pulse Education Prize for 2001$3,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Jennette Sakoff
SchemeResearch Grant
RoleLead
Funding Start2001
Funding Finish2001
GNoG0181503
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

20003 grants / $45,000

Influence of Haematopoetic stem cell telorase activity on bone marrow recovery following myoablative therapy.$20,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Lisa Lincz, Ms Kerry Fagan, Doctor Jennette Sakoff
SchemeResearch Grant
RoleInvestigator
Funding Start2000
Funding Finish2000
GNoG0180171
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

A counter-intuitive anticancer treatment.$20,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Jennette Sakoff
SchemeResearch Grant
RoleLead
Funding Start2000
Funding Finish2000
GNoG0180205
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

Young Medical Researcher of the Year.$5,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Jennette Sakoff
SchemeResearch Grant
RoleLead
Funding Start2000
Funding Finish2000
GNoG0180182
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

19991 grants / $25,000

Selective Inhibitors of Protein Phosphatases as Anti-cancer agents$25,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Jennette Sakoff, Professor Adam McCluskey, Conjoint Professor Stephen Ackland
SchemeResearch Grant
RoleLead
Funding Start1999
Funding Finish1999
GNoG0178390
Type Of FundingContract - Aust Non Government
Category3AFC
UONY
Edit

Research Supervision

Current Supervision

CommencedResearch Title / Program / Supervisor Type
2013Biomarker Discovery in Breast Cancer
Biological Sciences, Faculty of Science and Information Technology
Co-Supervisor
Edit

Dr Jennette Sakoff

Position

Conjoint Lecturer
Experimental Therapeutics Group
School of Environmental and Life Sciences
Faculty of Science and Information Technology

Focus area

Chemistry

Contact Details

Emailjennette.sakoff@newcastle.edu.au
Phone(02) 4921 1149
Fax(02) 4968 0384

Office

BuildingDepartment of Medical Oncology
LocationCalvary Mater Newcastle Hospital

,
Edit